Welcome to our dedicated page for Cvrx news (Ticker: CVRX), a resource for investors and traders seeking the latest updates and insights on Cvrx stock.
CVRx, Inc. (NASDAQ: CVRX) is a commercial-stage medical device company whose news flow centers on its Barostim neuromodulation platform for cardiovascular disease, particularly heart failure. The company regularly issues press releases and investor updates detailing financial performance, operational metrics and developments related to Barostim.
Readers of CVRX news can expect recurring coverage of quarterly and annual financial and operating results, including revenue trends, gross margin, operating expenses, cash and cash equivalents, and the growth of active implanting centers and sales territories in the U.S. and Europe. The company also reports on reimbursement milestones, such as the transition of Barostim procedures to Category I CPT codes and CMS decisions affecting outpatient payment classifications and physician fee levels.
Another key theme in CVRx news is clinical and regulatory progress. The company has highlighted FDA actions such as the Breakthrough Device designation for Barostim and the grant of an Investigational Device Exemption for the BENEFIT-HF trial, a randomized controlled study designed to evaluate Barostim’s impact on outcomes in an expanded heart failure population. Updates on applications to the Centers for Medicare & Medicaid Services for trial coverage and other reimbursement-related developments are also part of the company’s announcements.
CVRx news releases frequently mention participation in major healthcare and investor conferences, where the management team presents the company’s strategy and Barostim-related data to the investment community. For investors and observers following CVRX, this news page provides a centralized view of earnings releases, reimbursement and coding changes, clinical trial plans, financing arrangements, and conference appearances linked to the company’s heart failure therapy platform.
CVRx announced preliminary results from the BeAT-HF trial, assessing the Barostim device for heart failure treatment. The trial included 323 patients, comparing Barostim + medical therapy to medical therapy alone. While the primary endpoint was not statistically significant, additional analyses indicated potential benefits, including improved all-cause survival and quality of life. The safety profile of Barostim remained robust over 24 months. CVRx intends to submit these findings to the FDA for expanded labeling. The results will be discussed in a conference call on February 21, 2023, and presented at the THT Conference on March 21, 2023.
CVRx reported a remarkable 96% increase in fourth-quarter revenue, totaling $7.2 million compared to the previous year. Heart Failure (HF) revenue surged 121% to $6.0 million, driven by expansion into new territories and heightened awareness of Barostim. Total 2022 revenue reached $22.5 million, up 72%. The number of active implanting centers rose from 46 to 106, a 130% increase. However, the company faced a net loss of $10.5 million in Q4. For 2023, CVRx anticipates total revenue between $35 million and $38 million and gross margins of 78%-79%.
CVRx, Inc. plans to release its fourth quarter and full year 2022 financial results after market close on January 26, 2023. A conference call will follow at 5:30 p.m. Eastern Time to discuss the results, which will be available via webcast. CVRx focuses on innovative neuromodulation solutions for cardiovascular diseases, specifically the Barostim device, the first FDA-approved technology using neuromodulation to treat heart failure symptoms. Barostim has received FDA Breakthrough Device designation and is CE Mark approved for additional indications.
CVRx, Inc. announced preliminary unaudited revenue results for Q4 and full year 2022. Q4 revenue is estimated between $7.0M and $7.1M, up approximately 91% to 94% from Q4 2021. Full year 2022 revenue is anticipated to be $22.3M to $22.4M, a 71% to 72% increase from 2021. The company reported 106 active implanting centers and expects 2023 revenue between $35.0M and $38.0M with gross margins of 78% to 79%. Cash reserves stood at $106 million as of December 31, 2022.
CVRx, a medical device company focused on neuromodulation solutions for cardiovascular diseases, will present at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 pm Pacific Time. The presentation will be available via a live audio webcast, with a replay accessible for 30 days. CVRx's flagship product, Barostim, is an FDA-approved device designed to reduce heart failure symptoms by improving autonomic nervous system balance through electrical pulses to baroreceptors in the carotid artery. For more details, visit ir.cvrx.com.
CVRx, Inc. announced the appointment of Kevin Hykes to its Board of Directors effective December 21, 2022. Hykes brings over 30 years of experience in the medical device sector, having held leadership roles in several companies, including Augmedics and Bardy Diagnostics. His expertise is expected to bolster CVRx's efforts to enhance the global reach of Barostim™, a neuromodulation device aimed at improving heart failure symptoms. The management expresses optimism regarding the impact of Hykes' leadership on the company's growth trajectory.
CVRx, a medical device company focused on neuromodulation solutions for cardiovascular diseases, will participate in the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 8:00 am Eastern Time. The presentation will be available via a live audio webcast on the company’s investor relations page. CVRx’s primary product, the Barostim™ System, is the first FDA-approved medical technology using neuromodulation to alleviate heart failure symptoms. The device has received FDA Breakthrough Device designation and CE Mark approvals for heart failure and resistant hypertension.
CVRx has launched the new Barostim NEO2 Implantable Pulse Generator (IPG) in the U.S., enhancing patient and physician experiences during heart failure therapy. The device is 10% smaller and offers a 20% increase in battery life, reducing replacement frequency. It features a simplified design with a single lead port, improving implantation ease. The Barostim NEO2 retains the clinically proven Barostim Therapy while providing a more convenient option for patients and healthcare providers.
CVRx, a medical device company specializing in neuromodulation solutions for cardiovascular diseases, will participate in two investor conferences on November 17, 2022, in New York, NY. The conferences include the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum and the 13th Annual Craig-Hallum Alpha Select Conference. CVRx's flagship product, Barostim, is the first FDA-approved technology aimed at treating heart failure through neuromodulation, and it has also received CE Mark approval in Europe.
CVRx reported third quarter 2022 revenue of $6.2 million, an 82% increase year-over-year. U.S. Heart Failure revenue nearly doubled to $4.9 million, driven by an expansion in sales territories and increased awareness of Barostim. Active implanting centers in the U.S. grew to 91, a 28% increase from the previous quarter. Gross profit rose to $4.8 million with a gross margin of 78%. However, the net loss widened to $9.8 million. The company expects 2022 revenue between $21.8 million and $22.3 million, with a new $50 million debt facility in place.